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ABSTRACT
ANNA GRACE SKUBIZ: The Effect of Glutamine on Metabolism of Metastasis in
Different Organ Microenvironments.
(Under the direction of Dr. Mika Jekabsons)
Malignant breast cancers exhibit preferential metastasis to bone and lung (1). While
changes in gene expression in lung-specific (LM) and bone-specific metastasis (BoM)
lines derived from the MDA-MB-231 breast cancer line have been identified, few
metabolic genes are differentially expressed; thus it is unknown if tissue-specific
metabolic reprogramming occurs. Two hallmarks of cancer cells are an altered metabolic
phenotype characterized by enhanced conversion of glucose to lactate in spite of adequate
oxygen availability for complete mitochondrial oxidation of this substrate (referred to as
aerobic glycolysis or the Warburg effect) and a greater dependence on glutamine. These
changes in primary tumor metabolism are crucial for cancer cell metastasis by increasing
the supply of glycolytic and tricarboxylic acid (TCA) cycle intermediates that are
necessary for de novo biosynthetic pathways. I hypothesize that the LM and BoM lines
exhibit metabolic reprogramming to allow for proliferation in the lung and bone
microenvironments, respectively. The rates of glucose consumption, mitochondrial
respiration, and lactate production were determined for MDA-MB-231, LM, BoM, and
the less aggressive T47D lines given either glucose or glucose and glutamine as the
exogenous substrates. Aerobic glycolysis for the BoM and LM lines, was greater than the
MDA231 and T47D lines. Respiration rate was significantly lower in the BoM and LM
lines. Glutamine consumption normalized to glucose consumption was significantly
lower for BoM cells, suggesting this line has a lower preference for glutamine. Glutamine
had significant main effects on glucose uptake, lactate production, and a near significant
4

effect on aerobic glycolysis; the effect of glutamine on mitochondrial respiration was cell
line dependent, as this substrate tended to reduce T47D and MDA231 respiration while
increasing it in LM cells. These data indicate that the LM and BoM sub-clones have
different metabolic phenotypes than the parent MDA-MB-231 cells and the extent of the
differences is affected by glutamine. Further, the LM and BoM phenotypes differ from
each other given their responses to exogenous glutamine. Successful growth of metastatic
cells from a primary tumor in secondary organs such as lung and bone may thus require
metabolic plasticity characterized by higher aerobic glycolysis and lower mitochondrial
activity.
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INTRODUCTION
Transcriptomic studies have identified unique gene expression profiles in sub-clones of
metastatic tumors that preferentially invade different organs (1). Individual cells within
the MDA-MB-231 metastatic breast cancer line have unique gene expression profiles and
thus are genetically heterogeneous. Such heterogeneity contributes to the probability of
invasion of the lungs, bone, and brain (2). Specific genes that mediate breast cancer
metastasis to the bones and lungs (3) have been identified that facilitate one or more of
the following processes of metastasis: intravasation, adhesion, extravasation,
angiogenesis, and finally growth in a distant tissue (2). Notably, a prerequisite for
successful growth in a distant tissue is a metabolic infrastructure capable of meeting the
demands for substrates and energy in an environment that may differ from the tissue in
which the original tumor developed (Fig. 1). There is evidence that triple negative breast
cancer cells such as the MDA-MB-231 line have the capacity to adjust their metabolic
phenotype upon detachment from the primary tumor (4). However, it is unclear if unique
metabolic adaptations occur as metastatic cells invade different secondary organs.
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Cells that detach from the primary tumor and circulate in the blood have changes in
metabolism, specifically increases in mitochondrial biogenesis and respiration.

Figure 1: Diagram of glycolysis and the tricarboxylic acid cycle. Notable intermediates are given. J 0, J4, J10, and JRR were
the measured fluxes for glucose consumption, lactate production, glutamine consumption, and respiration rate which
were the focuses of this experiment.

This indicates that cells leaving the primary tumor have differing metabolic properties
that may depend on the immediate environment (4). While glucose and glutamine are
important for growth of most cancers, the pathways through which these substrates are
processed may change with the microenvironment (Fig. 1). The fraction of glucose used
10

for the pentose phosphate pathway, fatty acid synthesis, or oxidation by mitochondria can
vary depending on reactive oxygen species (ROS) production, availability and uptake
capacity of exogenous fatty acids, and the degree of mitochondrial dysfunction.
Similarly, the fraction of glutamine used for protein, glutathione, or fatty acid synthesis,
and for oxidation by the tricarboxylic acid (TCA) cycle and/or malic enzyme can vary
depending on ROS production and availability of other substrates. The number of
tumorigenic genes that contribute to metabolic changes seen in cancer has yet to be
resolved (5), but hypoxia inducible factor-1 (HIF-1) has a major role as a ‘master
regulator’ of glucose metabolism. It promotes glycolytic activity by upregulating glucose
transporters (GLUT) and multiple glycolytic genes. HIF-1, in coordination with AMP
activated protein kinase (AMPK), regulates glucose uptake used for glycolysis and the
TCA cycle. The variations in HIF-1 and AMPK activities, together with mitochondrial
reactive oxygen species (ROS) signaling, can lead to metabolic plasticity in cancer and
may partly explain the differences in glucose and glutamine uptake, lactate production,
and mitochondrial respiration observed in different cancers. This has been shown in
breast cancer cells having high expression of HIF-1 and AMPK that produce lactate at a
higher rate compared to benign cells (4). Specifically, HIF-1α is responsive in cancer cell
hallmarks such as angiogenesis but is also highly involved in metabolism (6).
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MDA-MB-231 gene expression exhibits a typical poor prognosis signature that is
associated with metastasis and resistance to radiation and chemotherapy. In vivo, such a
gene expression signature is thought to occur in only a small percentage of cells within
the breast tumor (1). Although a tumor may carry the poor prognosis signature, it is
proposed that organ specific metastasis is determined by different sets of genes (7). The
isolation of highly lung-, bone-, and brain-specific metastatic subclones from the
MDA231 cells has allowed progress on the mechanisms driving tissue-specific
metastasis. To date, most of the work has centered on gene expression differences but this
provides limited insight into the physiological differences between cells of the primary
tumor and those growing in secondary organs. The transformation of breast epithelial
cells to the metastatic MDA-MB-231 line involves changes in expression of multiple
metabolic genes, including isocitrate dehydrogenases-1 and -2 (IDH1, IDH2), fumarate
hydratase (FH), and the succinate dehydrogenase (SDH) complex. Additionally,
expression of voltage-dependent anion channel 1 (VDAC1), which allows for metabolite
and ROS exchange between mitochondria and cytoplasm, is essential for the growth of
cancer cells such as MDA. This demonstrates that coordinated changes to the expression
of metabolic genes are important for the physiology of cancer cells in general and
furthermore subtle changes may be important for the lung, bone and brain metastatic
subclones, but no metastatic preferences have been noted (6).
12

Primary tumors that metastasize to different organs over- or under-express a common set
of genes, including COX2, MMP1, ANGPTL4, LTPB1 (controls TGFβ activation),
FSCN1, and RARRES3. Breast cancers that often metastasize to the lungs (3)
overexpress COX2 and MMP1 along with 48 other genes mentioned in the Minn study.
The most notable of this group are ID1, CXCL1, along with COX2 and MMP1 because
they are directly and almost exclusively correlated with lung metastasis. These genes
assist in invasion through mediation of cell signaling and intracellular modulation of gene
expression. Additionally, a decrease in ID1, VCAM1, or IL13Rα2 has been shown to
drastically decrease preferential metastasis to lung (7). It is unclear how the majority of
overexpressed genes are involved in facilitating lung metastasis, and notable that none of
the identified genes have a role in glucose or glutamine metabolism. There are similar
numbers of overexpressed genes unique to bone metastasis; furthermore, there is limited
overlap in which genes aid the invasion of bone and lung tissue (3). CXCR4, CXCL12
and RANKL are overexpressed in breast cancers that metastasize to bone; the latter two
are known to stimulate mammary tumor growth (5). CXCL12 is a regulator of
hematopoiesis and has been proposed to regulate the immune system to influence
metastasis. IL11 and OPN overexpression significantly increase MDA-MB-231
metastasis to bone. There is a proposition that TGFβ may further stimulate this
metastasis, contrary to its expected role as a tumor suppressor. TGFβ increases already
13

overexpressed IL11 and CTGF in populations highly metastatic to bone further
supporting tumor progression (8). While many of these genes have a role in cell signaling
(7), the impact on metabolism remains unknown.

One of the most unique metabolic properties of cancer cells is the Warburg effect. Otto
Warburg found that even in the presence of oxygen, cancer cells ferment glucose to
lactate (the glycolytic index) at extremely high rates (17). This effect is thought to be
important to increase supply of glycolytic intermediates for different biosynthetic
pathways. Further, glutamine is consumed at a rate one to two orders of magnitude higher
than in untransformed cells (9). It is essential for the survival and proliferation of most
cancer cells by sustaining both ATP synthesis and biosynthetic pathways (10, 11). In
1955 it was found that proliferating tumor cells have a high demand for glutamine (9).
The focus of this research is to identify the metabolic differences that may exist between
cell lines in the absence or presence of glutamine and the impact glutamine makes on
metabolic processes.
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METHODS
A. Cell lines and culture
Metastatic breast cancer MDA-MB-231 cells (hereafter referred to as MDA231) and the
less aggressive T47D breast cancer cells were provided by Dr. Y.D. Zhou (University of
Mississippi, Department of Chemistry and Biochemistry). Sub-clones of MDA231 cells
that preferentially metastasize in lung (LM) and bone (BoM) were generated by
Massague’s lab (12, 13). Both LM and BoM cells were obtained from Dr. Kounosuke
Watabe (Wake Forest University) and provided by Dr. Zhou. Cells were routinely
cultured using RPMI-1640 media supplemented with 10% fetal bovine serum and 0.5%
vol/vol penicillin-streptomycin in 10 cm polystyrene petri dishes at 37oC in a humidified
5% CO2 incubator. Cells were maintained in culture for no more than 20 passages, and
typically split twice a week. The day before each experiment, approximately 1.0 x 10 6
cells were seeded in each well of 2-well Lab-Tek chambers. Control wells received 2mL
standard cell culture media while treatment wells were incubated in glutamine-free
RPMI-1640 media supplemented with 1.5 mM 5-13C glutamine. Cells were incubated for
20-22 hours prior to experiments.
B. Materials

Glutamate pyruvate transaminase, glucose-6-phosphate dehydrogenase (G6PDH), lactate
dehydrogenase, nicotinamide adenine dinucleotide phosphate (NADP), nicotinamide
15

adenine dinucleotide (NAD), adenosine triphosphate (ATP), and 2 oxoglutarate were
purchased from Calzyme (San Luis Obispo, CA). Hexokinase and microbial glutamate
dehydrogenase were purchased from Sigma (St. Louis, MO). Glutaminase was purchased
from Megazyme (Chicago, IL). 5-13C glutamine was purchased from Cambridge Isotopes
(Tewksbury, MA). Cell culture media, fetal bovine serum, and cell culture supplies were
purchased from Fisher Scientific (Pittsburg, PA). Buffers and other general reagents were
purchased from Sigma.
C. Flux experiments
After overnight incubation in cell culture media  5-13C glutamine, cells were rinsed then
equilibrated 5 h 37oC in experimental buffer containing 137 mM NaCl, 5 mM KCl, 20
mM TES, 1.3 mM CaCl2, 1.3 mM MgCl2, 1.2 mM Na2SO4, 0.4 mM KH2PO4, 0.2 mM
NaHCO3, 5.5 mM glucose, 0.3 % fatty acid-free bovine serum albumin (BSA),  1.5 mM
5-13C glutamine, pH 7.4. The control buffer contained no glutamine. Respiration rate of
cells in each well was determined at 37oC in 2.15 mL fresh buffer using a custom-made
setup with a Clark-type micro-oxygen electrode (Micrelectrodes, Inc., Bedford MA) (Fig.
2. Data for each well was acquired over 45-55 min. with a Powerlab A/D unit and Lab
Chart software (AD Instruments). Cells were rinsed once with buffer then serially
incubated for 60 min, 120 min, and 60 min at 37oC with 350 L buffer. After each
incubation period, buffer was collected in microfuge tubes on ice, the cells were rinsed
once, and then 350 L buffer added for the next incubation period. Control wells without
cells were incubated in parallel to correct for evaporative volume changes over each
incubation period. The samples were centrifuged for 5 min. 4oC at 21,000 xg and
supernatants stored at -20oC for metabolite assays. The 60 min incubations were used to
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assess average rates of glucose consumption and lactate production, while all three were
used to assess glutamine consumption. Cell pellets were visible for the MDA231
samples; these were saved and assayed for protein content to correct for protein loss over
each incubation period. After the final incubation, wells were rinsed once with 1 ml
phosphate buffered saline (PBS) then solubilized for 15 min at 37oC with 500 L 50 mM
NaCl, 20 mM TES, 1% SDS, pH 7.3. The extracts were vortexed 2-3 min. then
centrifuged 10 min. 21,000xg 10oC and the supernatants stored at -20oC for protein assay.
The MDA231 cell pellets were washed once with 200 L PBS, repelleted by
centrifugation, then solubilized with 100 L SDS buffer and stored at -20oC.

Figure 2: Set up for respiration measurement. Shown are the cells plated at the bottom of chamber. A stir bar located
in the media is being turned by a magnetic stirrer on the other side of the cell chamber lid. In the container is an O 2
electrode which measures the decreasing oxygen concentration of the buffer.

D. Metabolite assays
D.1. Glucose Assay
Buffer glucose concentrations were determined by enzymatic assay. Samples (5 µl) were
run in triplicate in assay buffer (115 µl) containing 100mM triethanolamine, 7 mM
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MgCl2, 2 mM ATP, 2 mM NADP, 1 U/mL glucose-6-phosphate dehydrogenase, 1 U/mL
hexokinase, pH 7.3. Following a 10min incubation, fluorescence was quantitated using a
Shimadzu RF-6000 spectrofluorophotometer (ex=341 nm, em=464 nm, excitation and
emission slits 5nm and 15nm, respectively). Glucose standards (3.5, 4.0, 4.5, 5.0, 5.5, and
6.0 mM) were prepared in experimental buffer and run in parallel.
D.2. Glutamine Assay
Glutamine concentrations were determined by a two-step enzymatic reaction. For the first
reaction, duplicate samples (6 µL) were incubated 45 min at 37oC in reaction buffer (34
µL) containing 60 mM sodium acetate, with or without 1 U/mL glutaminase, pH 4.5.
Reactions without glutaminase served as controls to quantitate background ammonia
production by the cells, which was subtracted to obtain the glutamine-derived ammonia.
The second reaction was initiated by adding 80 µL of 300 mM Tris, 10 mM 2oxoglutarate, 240 µM NADPH, and 2 U/mL microbial L-glutamate dehydrogenase, pH
8.5 to each sample. After 60 min incubation protected from light, fluorescence was
quantitated using a Shimadzu RF-6000 spectrofluorophotometer (ex=341 nm, em=464
nm, excitation and emission slits of 10nm). Glutamine standards (0, 0.2, 0.4, 0.8, 1.2, 1.6,
and 2.0 mM) were prepared in experimental buffer and run in parallel.
D.3. Lactate Assay
Buffer lactate concentrations were determined by enzymatic assay. Samples (5 µL) were
run in triplicate in assay buffer (115 µL) containing 100 mM glycylglycine, 100 mM
glutamate, 2 mM NAD, 1 U/mL lactate dehydrogenase, and 1 U/mL glutamate pyruvate
transaminase, pH 8.5. Following a 40min incubation fluorescence was quantitated using a
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Shimadzu RF-6000 spectrofluorophotometer (ex=341 nm, em=464 nm, excitation and
emission slits 15nm and 20nm, respectively). Lactate standards (0, 0.5, 1.0, 1.5, 2.0, and
2.5 mM) were prepared in experimental buffer and run in parallel.
D.4. Protein Assay
Quantitation of total protein in soluble cell extracts (duplicates, diluted 1:3 in water) were
determined by bicinchoninic acid (BCA) assay. Reactions (25 µl sample with 500 µl
BCA reagent) were incubated for 30 min, 60oC, cooled, and quantitated at 562 nm using
a Ultrospec 3100pro spectrophotometer (Amersham Biosciences). Bovine serum albumin
standards (0, 50, 100, 150, 200, 300, 400, and 500 ug/ml) dissolved in solubilization
buffer were run in parallel. Additionally, protein assays were run for the MDA cell
pellets to correct for protein lost over each incubation period. The MDA cells have a
much lower adherence to the plate than the three other lines. Due to this inequality MDA
cells were spun into pellets and assayed to measure the protein content as a form of
compensation to account for the cell loss during the experiment.
D.5. Statistics
For each variable, two-way analysis of variance (ANOVA) was run to assess main effects
of cell line and treatment (glutamine) and cell line x treatment interaction. When
significant main effects of cell line were observed, differences between the cell lines
within a treatment (i.e., either with or without glutamine) were assessed by one-wayANOVA with Tukey’s post-hoc test. Significant effects of glutamine on a particular cell
line were assessed by paired T-test. P<0.05 was taken as the level of significance.
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RESULTS
Table 1: 2-way ANOVA p-values for the main effects of treatment ( glutamine), cell line, and treatment x cell line
interaction for the measured variables.

A. Glucose uptake
Glucose is a primary substrate used by tumor cells for energy homeostasis by ATP
synthesis, redox homeostasis by NADPH and NADH synthesis, and for anabolic
processes such as nucleotide, fatty acid, and amino acid synthesis. The rate of glucose
uptake is thus an important indicator of overall tumor cell metabolism. For all
experiments, glucose concentrations decreased anywhere from 0.5-2.0 mM, so the
concentrations did not change by more than about 40% of the initial concentration (5.5
mM). Since the Km for GLUT1, the most prevalent glucose transporter, is about 1-2 mM,
this change should have little effect on uptake rate, so the rates were calculated assuming
steady-state conditions over each 60 min. period.
Without glutamine present, glucose uptake rate was, as anticipated, significantly lower
for the least aggressive, slow growing T47D cells than the three metastatic lines (Fig. 3).
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LM and BoM uptake rates were not different (p=0.39), but both were significantly lower
than the parent MDA231 cells. In the presence of glutamine, all four cell lines differed
significantly from each other. Glutamine tended to decrease glucose uptake in three of the
lines, which accounts for the significant main effect of glutamine treatment on glucose
uptake (Table 1); BoM and MDA231 cells tended to have lower rates of glucose uptake
(p=0.14 and p=0.07, respectively by paired t-test with no glutamine treatment) while
T47D uptake was significantly lower (p=0.01). The LM uptake rate was insensitive to
glutamine, and this together with the tendency toward lower BoM uptake resulted in a
significant difference (p=0.002) between these lines (Fig. 3. These data suggest that the
LM and BoM sub-clones may have a different metabolic phenotype than the parent
MDA231 cells from which they were derived, and the extent of this difference is affected
by glutamine.

21

Figure 3: Glucose uptake for each cell line incubated with or without glutamine. Buffer glucose concentrations were
determined by enzymatic assay and rates averaged over two 60 min. incubations. Rates were normalized to total SDSsoluble protein. Data are mean  standard error (n=4). Within a treatment, means sharing the same letter are not
significantly different. Asterisks above a letter denote significant difference with the corresponding cell line in
glutamine-free buffer.

B. Lactate production
Lactate is a primary end product of glucose metabolism that is produced at greater rates
when oxygen becomes limiting for mitochondrial oxidative phosphorylation and hence is
an indicator of anaerobic metabolism. However, cancer cells have been found to produce
more lactate than untransformed cells, even when oxygen is not limiting for oxidative
phosphorylation. This is known as the Warburg effect or more commonly aerobic
glycolysis. Lactate production has been linked to metastasis formation, evasion of
immune response, angiogenesis and chemoresistance (14). These traits, unique to cancer
cells have made lactate production a key indicator of metastatic progression. For these
experiments, lactate accumulation ranged from 0.5-2.5 mM over the 60 min. incubations.
The rates of efflux were assumed to be constant over this time period, but the higher
22

concentrations accumulated in some experiments with LM cells could negatively affect
efflux rate given that the rate and direction of transport by the monocarboxylate
transporter depends partly on the plasma membrane lactate gradient.
Without glutamine, differences in lactate production were similar to that of glucose
consumption. The more metastatic MDA231, BoM and LM lines produced lactate at a 23 fold greater rate than T47D cells (Fig.4). LM rate was between and not different from
either the MDA231 (p=0.53) or BoM (p=0.10) lines, while the latter two lines differed
significantly (p=0.01). In the presence of glutamine, T47D, MDA231, and LM lactate
production decreased significantly, whereas BoM rate was unchanged. The lower
MDA231 and LM rates resulted in no differences between the three aggressive metastatic
lines. This suggests that the rates of aerobic glycolysis in these three lines may be the
same. Additionally, the effect of glutamine may indicate that MDA231 and LM lines rely
more on this substrate for ATP synthesis by oxidative phosphorylation than BoM cells.
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Figure 4: Lactate production rate for each cell line incubated with or without glutamine. Buffer lactate concentrations
were determined by enzymatic assay and rates averaged over two 60 min. incubations. Rates were normalized to total
SDS-soluble protein. Data are mean  standard error (n=4). Within a treatment, means sharing the same letter are not
significantly different. Asterisks above a letter denote significant difference with the corresponding cell line in
glutamine-free buffer.

Lactate production provides an absolute estimate of aerobic glycolysis, but normalizing
lactate production to glucose consumption reports the proportion of glucose converted to
lactate, known as the glycolytic index, and is a better measure of comparing aerobic
glycolysis between cell lines. Cancer cells are known to have a higher glycolytic index
than untransformed cells, possibly to support tumor growth by increasing the supply of
glycolytic intermediates used for anabolic reactions. More aggressive, metastatic tumors
typically have a higher glycolytic index. Without glutamine, this was the case (Fig. 5);
furthermore, the LM and BoM ratios were significantly, or borderline significantly,
higher than the parent MDA231 line. Glutamine did not affect the T47D or BoM ratios,
either because the cells were insensitive to glutamine (BoM) or both glucose
consumption and lactate production were reduced proportionally (T47D). The MDA231
and LM glycolytic indexes were lower (although not significantly, p=0.12 and p=0.07,
24

respectively), with the latter most affected because glutamine reduced lactate production
without affecting glucose uptake (Figs. 3 and 4); this explains this near-significant
(p=0.06) main effect of glutamine (Table 1). Somewhat surprisingly, the MDA231 index
did not differ from T47D cells (p=0.58), whereas LM and BoM cells remained
significantly greater. These data suggest that the BoM and LM lines convert a greater
proportion of the glucose they consume to lactate, and hence have a higher ‘normalized’
aerobic glycolysis than the MDA231 line.

Figure 5: The lactate to glucose ratio, otherwise known as the glycolytic index, shown across cell lines with and
without glutamine. The buffer concentration was determined by taking data from the previous graphs into a ratio.
Rates were normalized to total SDS-soluble protein. Data are mean  standard error (n=4). Within a treatment, means
sharing the same letter are not significantly different. Asterisks above a letter denote significant difference with the
corresponding cell line in glutamine-free buffer.

C. Mitochondrial Respiration Rate
Respiration rate of cells attached to the bottom of the Lab-Tek chambers was measured
with a custom oxygen electrode setup prior to incubations to determine glucose, lactate,
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and glutamine rates (Fig. 2). Mitochondrial respiration rate was determined by
subtracting non-mitochondrial oxygen consumption that had been previously determined
in Seahorse Extracellular Flux Analyzer experiments as rotenone plus antimycin A
insensitive rates (Y.D. Zhou, personal communication; for T47D, MDA231, BoM, and
LM lines, the fraction that was non-mitochondrial was 0.230.01, 0.110.02, 0.090.05,
and 0.230.05, respectively; meanstandard error, n=8). Since the oxygen consumed is
used at the end of the electron transport chain as an electron acceptor, and the electrons
are derived from substrates oxidized within the mitochondrial matrix, respiration rate is
an indirect measure of substrate oxidation rate in this organelle.
Without glutamine, respiration rate differed significantly among all four lines.
Surprisingly, the greatest differences were between the MDA231 cells and the LM/BoM
sub-clones, which had 3-4-fold lower rates (Fig. 6). While there was no significant main
effect of glutamine on respiration rate, the treatment x cell line interaction was significant
(Table 1). This was the result of glutamine tending to stimulate LM (p=0.12) but reduce
T47D (p=0.06) and MDA (p=0.14) respiration. Because of the stimulation by glutamine,
LM and BoM rates were not different, but significantly lower than the T47D and
MDA231 rates. It is interesting to note that glutamine tended to lower the lactate: glucose
ratio for both MDA231 and LM cells, suggesting lower anaerobic glycolysis, but
oppositely affected LM and MDA231 mitochondrial activity. This data does imply that
the sub-clones of MDA231 rely far less on oxidative phosphorylation as a source of ATP
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than the parent line.

Figure 6: Cellular respiration rate for each cell line incubated with or without glutamine. Buffer oxygen
concentrations were determined through apparatus measurements, rates averaged over two 60 min. incubations. Rates
were normalized to total SDS-soluble protein. Data are mean  standard error (n=4). Within a treatment, means
sharing the same letter are not significantly different. Asterisks above a letter denote significant difference with the
corresponding cell line in glutamine-free buffer.

Respiration rate normalized to glucose uptake provides an assessment complementary to
the lactate: glucose ratio on the glycolytic index of different cell lines. For cells that
divert more glucose to lactate, less mitochondrial activity might be expected since
relatively more ATP will be supplied by glycolysis; cells with higher lactate: glucose
ratio are thus predicted to have a lower respiration: glucose ratio. In general, this
prediction held true for these four cell lines, both with or without glutamine. The T47D
line, which had the lowest lactate: glucose ratio, had the highest respiration rate to
glucose ratio. MDA231 is the second highest ratio (Fig. 7). Conversely, the BoM and LM
lines having the highest lactate: glucose ratios had the lowest respiration rate: glucose
ratios. These data further suggest that the lung and bone metastatic sub-clones have
27

greater anaerobic glycolysis and lower oxidative phosphorylation than the parent
MDA231 line.

Figure 7: This figure shows the respiration rate to glucose ratio. The buffer concentration was determined by taking
data from the previous graphs into a ratio. Rates were normalized to total SDS-soluble protein. Data are mean 
standard error (n=4). Within a treatment, means sharing the same letter are not significantly different. Asterisks above
a letter denote significant difference with the corresponding cell line in glutamine-free buffer.

D. Glutamine Uptake
Glutamine, like glucose, can be used for ATP, nucleotide, fatty acid, and amino
acid/protein synthesis. Cancer cells are known to consume excess glutamine compared to
other cells, to support these more active anabolic processes. A main fate of glutamine is
to mitochondria for supply of TCA cycle intermediates citrate, malate, and oxaloacetate.
Glutamine uptake is generally much lower than the rate of glucose consumption, so for
these assays 120 min incubations were also used to ensure detectable changes in
glutamine concentrations. Since the rates assessed over 120 min were similar to that over
60 min, these were averaged to obtain the uptake rates.
28

Glutamine uptake was highest in the MDA231and LM lines. Surprisingly, BoM uptake
was significantly lower and no different from T47D cells despite the more glycolytic,
proliferative phenotype of the BoM line (Fig. 8).

Figure 8: Glutamine uptake rate for each cell line incubated with glutamine. Buffer glutamine concentrations were
determined through enzymatic assay, rates averaged over two 60 min. incubations. Rates were normalized to total
SDS-soluble protein. Data are mean  standard error (n=4). Within a treatment, means sharing the same letter are not
significantly different. Asterisks above a letter denote significant difference with the corresponding cell line in
glutamine-free buffer.

Glutamine rates were normalized to glucose rates to assess the relative importance of
glutamine as a substrate. The more rapidly proliferating LM and BoM lines were
predicted to have higher glutamine: glucose ratios given the importance of glutamine in
supporting multiple anabolic pathways. Contrary to the prediction, the BoM ratio was
significantly lower while the T47D line was no different from the more aggressive
MDA231 and LM lines (Fig. 9). These data suggest that the more metastatic lines do not
have a greater preference for glutamine.
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There is no significant difference in the glutamine to glucose ratio of T47D, LM, or
MDA cells. BoM cells are the exception in this measurement being the only line
considered to have a different level of glutamine to glucose consumption.

Figure 9: The glutamine to glucose ratio shown across cell lines with 13C glutamine. The buffer concentration was
determined by taking data from the previous graphs into a ratio. Rates were normalized to total SDS-soluble protein.
Data are mean  standard error (n=4). Within a treatment, means sharing the same letter are not significantly
different. Asterisks above a letter denote significant difference with the corresponding cell line in glutamine-free buffer.

F. Protein content
From the 5 h pre-equilibration in experimental buffer through the three incubation
periods used to assess glucose, lactate, and glutamine rates, cells were either treated
without or with glutamine for approximately 11 h. Protein content was used as a
measurement of total cell number to normalize all uptake rates. However, since the
duration of these experiments was approximately 11 h, it was of interest to determine
whether the presence of glutamine over this time period significantly affected the
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proliferation of each cell line compared to the glutamine deprived controls. There was a
significant increase in protein content of MDA231 (p<0.01) and BoM (p=0.03) lines
given glutamine, whereas glutamine did not affect T47D and LM protein content. The
effect on BoM cells was unexpected given this line had lower preference for glutamine
relative to glucose than the other three lines (Fig. 10). Although there were significant
differences within two cell lines, there was no significant main effect of glutamine on the
protein content by 2-way ANOVA (Table 1). It should be noted that each line was seeded
at 0.9-1.1 million cells per well for these experiments, so the expectation was that protein
content should be similar between the lines. This was true for T47D, BoM, and LM cells,
but the MDA231 content was significantly lower. This was attributed to the fact that
MDA231 cells are known to adhere more loosely to cell culture wells, and not make cellcell contacts due to poor expression of cadherins. Their weaker attachment was reflected
in the cell pellets that were consistently recovered with this cell line following each
incubation period (protein content in these pellets was quantitated to correct for this loss
over each experiment). Thus, a significant number of MDA231 cells seeded in each well
likely never attached and were washed from the well prior to the experiments.
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Figure 10: Protein concentration in soluble cell extracts for each cell line incubated with or without glutamine. Protein
concentrations were determined through BCA assay averaged over two 60 min. incubations. SDS-soluble protein was
used to normalize rates. Data are mean  standard error (n=4). Within a treatment, means sharing the same letter are
not significantly different. Asterisks above a letter denote significant difference with the corresponding cell line in
glutamine-free buffer.
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DISCUSSION
The overall goal of this research was to determine if metastatic sub-clones that
preferentially invade and grow in lung or bone tissue exhibit metabolic differences from
the parent MDA231 breast cancer line. Such metabolic plasticity may be important for
tumor growth in different tissue microenvironments, and may guide development of
tumor-specific, metabolic-targeted therapies. Potential metabolic differences were
evaluated by quantifying (a) rates of glucose and oxygen consumption as well as lactate
production, and (b) the rate of glutamine consumption, and the impact of exogenous
glutamine on the measured rates and total protein content. Metabolic reprograming from
a non-proliferative state is considered a hallmark of cancer that allows cells to redirect
nutrients such as glucose and glutamine for anabolic reactions while maintaining ATP
and redox homeostasis (15, 16). A major finding of this study is that the metabolic
phenotypes differ between the LM and BoM sub-clones and the MDA231 parent line.
The BoM and LM lines have a more aerobic glycolysis phenotype and less mitochondrial
activity compared to MDA231 cells. Moreover, LM cells appear to differ from BoM cells
in how they use glutamine. The data are consistent with further metabolic reprogramming
as tumor cells metastasize to different tissues.
Glucose and glutamine are important substrates for production of ATP and metabolites
necessary for many biosynthetic reactions to maintain cancer cell growth (17). Glucose is
the main substrate, however many become dependent on glutamine for redox homeostasis
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and fatty acid synthesis. Glucose is primarily metabolized through glycolysis to generate
seven distinct three-carbon metabolites, the last of which is pyruvate. One of the first of
these metabolites is glyceraldehyde-3-phosphate, which can be used to synthesize the
pentose phosphate sugars through the non-oxidative pentose phosphate pathway. 3phosphoglycerate, a key metabolite used for serine and glycine biosynthesis, is a second
important metabolite generated by oxidation of glyceraldehyde-3-phosphate in two
reactions that also yields the reduced cofactor NADH and ATP. NADH is the primary
source of electrons used to reduce pyruvate to lactate but can additionally be transported
into mitochondria through the malate-aspartate shuttle to provide electrons to the
respiratory chain. The three reactions downstream of 3-phosphoglycerate include the
enzyme pyruvate kinase that generates ATP and pyruvate from phosphoenolpyruvate.
Pyruvate can be transaminated to form alanine or transported into mitochondria for
complete oxidation for ATP synthesis or for fatty acid synthesis via the TCA cycle
metabolite citrate (17).
Glutamine metabolism is important as an entry point of carbon to replenish some of the
TCA cycle metabolites removed for anabolic reactions, but also serves as a substrate for
ATP synthesis (18). Although glutamine is not required for the viability of cancer cells, it
is important in allowing their continued proliferation by supporting protein, fatty acid,
and ATP synthesis (15). Glutamine is deaminated into ammonia and glutamate the latter
of which is oxidized into -ketoglutarate (α-KG), that is further processed in the TCA
cycle. α-KG can also be generated by transamination reactions of glutamate with
pyruvate or other organic acids. The amino group from glutamine, whether released as
free ammonia or transferred to other metabolites, can be used for nitrogen dispersal into
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non-essential amino acids, hexosamines, and nucleotides, all of which are important for
cell proliferation. Notably, glutamine can be used for cellular redox homeostasis as an
indirect substrate for glutathione synthesis or through conversion to the TCA cycle
metabolite malate, which is subsequently oxidized by malic enzyme to generate pyruvate
and NADPH; this cofactor is an important source of electrons for protection against
reactive oxygen species and for a number of biosynthetic reactions (17). A summary of
these metabolic pathways can be found in the introductory figure (Fig. 1).
T47D is a luminal less malignant breast cancer subtype that proliferates slowly and has a
low pathological grade amenable to chemo- and radiation therapies. In contrast, the
MDA231 line is a malignant triple negative breast cancer of basal cellular origin that has
an aggressive behavior with a poor prognosis once metastasis occurs (19). Highly
metastatic behavior is typically associated with phenotypically different metabolisms
(20). The results of this study support such a metabolic transformation with metastasis, as
MDA231 cells exhibited approximately 3-fold greater consumption of both glucose and
glutamine, as well as production of lactate. This is consistent with a previous study
showing MDA231 exhibits 2-3 fold higher glucose consumption and lactate production
than T47D cells (21). Higher glucose and glutamine consumption by MDA231 cells are
likely driven by a combination of increased consumption of glycolytic and TCA cycle
metabolites by a number of biosynthetic reactions and a higher overall ATP demand
because of greater ATP-dependent biosynthesis flux. The fact that glutamine significantly
increased MDA231 protein content while having no effect in T47D cells is consistent
with this substrate being important for support of biosynthesis reactions. This is further
supported by a recent report showing that glutamine enhances MDA231 growth (22).
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MDA231 cells overexpress SLC1A5 and SLC7A5 amino acid transporters that drive
glutamine uptake in a Na+-dependent and independent manner, respectively (23). The
fact that this uptake tended to lower glucose uptake, lactate production, the lactate:
glucose ratio (aerobic glycolysis) and mitochondrial respiration rate of both T47D and
MDA231 cells suggests that glutamine reduces overall cellular ATP production, and
correspondingly ATP consumption. For MDA cells, this is difficult to reconcile with the
fact that glutamine enhances total protein content and proliferation, which are expected to
increase ATP consumption. One possible interpretation of these data is that a significant
proportion of glutamine may be used for glutathione synthesis and redox homeostasis,
which could indirectly offset higher biosynthesis-linked ATP consumption. Availability
of glutathione is important for removal of hydrogen peroxide through glutathione
peroxidase and protection of protein thiols through glutaredoxin, both of which help to
maintain the cellular redox state. In doing so, the activities of the ubiquitin-proteasome
system and autophagy/mitophagy pathways for removal of damaged proteins and
mitochondria, both of which are ATP-dependent, could be reduced. Moreover,
homeostasis of the cellular redox state through glutathione availability may increase the
efficiency of mitochondrial oxidative phosphorylation (thereby increasing the ATP/O
ratio) and/or reduce respiratory chain electron leak to oxygen to form superoxide.
MDA231 cells have been found to be dependent on glutamine (22). The cells begin to
undergo apoptosis after two days without glutamine; however, they can survive without
glucose. This further supports the possibility that MDA231 cells use glutamine to
synthesize glutathione. High reactive oxygen species (ROS) production that is not
countered by adequate antioxidant defenses that include glutathione-dependent reactions
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can lead to Bax activation, cytochrome c release, and caspase-mediated apoptosis.
Glutamine may thus be important to MDA231 cells for both biosynthesis and defense
against oxidative stress.
Importantly, glutamine did not reduce overall ATP consumption in LM and BoM cells.
This could indicate that these cells have a lower ROS load, are less oxidatively stressed,
and hence require less glutathione. However, higher ATP consumption is predicted in
BoM cells given their modest but significantly greater protein content with glutamine;
this could indicate a modest effect of glutamine on antioxidant defenses and therefore the
proteasome-autophagy pathways. Notable, LM cell response to glutamine differed by
stimulating mitochondrial respiration and reducing aerobic glycolysis with no effect on
protein content. This suggests LM cells use glutamine primarily as a mitochondrial
substrate for ATP synthesis; stimulation of oxidative phosphorylation secondarily lowers
aerobic glycolysis through increasing the ATP/ADP ratio, a phenomenon known as the
Pasteur effect. This implies no significant demand for glutathione synthesis and hence
relatively low proteasome-autophagy activities. Further experiments are required to
assess the proportion of glutamine used for glutathione synthesis and the extent of ATP
consumption by the proteasome and autophagy pathways.
Unlike MDA, T47D does not require glutamine for cell proliferation and can survive
without it. This supports how T47D is not an aggressive metastatic cell line. It has been
shown to use NH4Cl as an alternative nitrogen source in glutamine deprived media (24).
Lactate production demonstrates a shift towards glycolytic flux (20). If considered for our
data it would presume that MDA has the highest glycolytic flux, followed by LM, then
BoM and finally T47D. High glycolytic flux and glucose consumption are associated
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with more aggressive metastatic lines and exhibit greater invasive behavior (20).
MDA231 has the highest lactate production, glucose consumption and respiration rate
which supports the aggressive nature of the cell line.
Lung and bone specific metastatic lines consumed glucose at significantly slower rates
than MDA231 cells yet had equivalent rates of lactate production. Therefore, the LM and
BoM lines shunt a higher proportion of glucose to lactate and have a more aerobic
glycolytic phenotype. Conversely, this implies that the MDA line uses more glucose for
purposes other than aerobic glycolysis. The oxidative and non-oxidative pentose
phosphate pathways are two major pathways that consume glucose to yield ribose
phosphates for nucleotide synthesis and NADPH for anti-oxidant defenses and redox
homeostasis. Preferential glucose use for NADPH synthesis is consistent with higher
ROS production by MDA cells and significant glutamine consumption for glutathione
synthesis. Most ROS are derived from mitochondria, which are substantially more active
in the MDA than LM and BoM lines. While it is tempting to speculate that the
differences in respiration rate account for differences in oxidative stress, mitochondrial
ROS production rate depends on a number of factors and is not simply a function of
respiratory chain activity. Substrate availability has an important impact on ROS
production, as substrate limited mitochondria tend to have more oxidized electron carriers
that would yield lower superoxide production. In this respect, it is worth speculating that
LM and BoM respiration rate may be low because mitochondria are substrate limited,
possibly due to limited capacity for pyruvate and/or glutamine transport into the matrix.
Such a limitation could explain a relatively lower use of glucose and glutamine in these
cell lines for NADPH and glutathione synthesis. Low mitochondrial activity in both LM
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and BoM lines could be an important metabolic adaptation allowing these lines to thrive
in lung and bone tissue, respectively. In vivo, lung and bone have received the highest
and lowest, respectively, mass-adjusted blood flows of all organs (Table 2). Oxygen
availability in the lungs (PO2 approximately 100 mmHg) is much higher than the systemic
tissues (PO2 approximately 20 mmHg) due to both the inordinately high blood flow and
the close proximity of alveolar air high in oxygen content, and crucially is one factor that
directly correlates with mitochondrial ROS production. LM growth in this high oxygen
environment may thus depend on limiting ROS production by restricted mitochondrial
substrate availability. Conversely, metabolically active BoM cells are expected to be in a
oxygen-limited environment because of limited blood flow to bone. BoM cells may
thrive in this environment because of gene expression changes that have minimized
reliance on mitochondrial activity for ATP production; if this occurs by limiting substrate
availability, a secondary consequence of this would be less ROS production.
Table 2: Comparison of mass-specific blood flow in different organs

Conclusion
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In summary, these results support the hypothesis that lung- and bone-specific metastatic
subclones exhibit significantly different metabolic phenotypes than the parent MDA-MB231 breast cancer line. The LM and BoM lines exhibited higher aerobic glycolysis and
lower mitochondrial respiration than MDA231 cells. Lower mitochondrial activity may
be important for LM adaptation to the high oxygen environment of the lungs to limit
production of reactive oxygen species. Conversely, it may be important for BoM
adaptation to the blood flow-limited environment of bone where restricted oxygen
availability is likely. Glutamine was an important anabolic substrate for MDA231 and
BoM cells, as total protein content was significantly increased compared to cells only
given glucose; in contrast, LM cells preferentially oxidized this substrate in
mitochondria. MDA231 aerobic glycolysis and respiration rate were lower with
glutamine, which was surprising given that these cells had greater protein content. One
possible explanation for this discrepancy is that MDA231 cells consume substantially
more glutamine for glutathione synthesis and protection against oxidative stress. Taken
together, growth of metastatic breast cancers in the lung and bone microenvironments are
associated with reduced mitochondrial activity and higher aerobic glycolysis. Metabolic
plasticity may thus be an important component to cancer metastasis.
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